Inovio Biomedical Company Description
Inovio Biomedical is electrifying patients with its drug delivery technology. The firm focuses on electroporation, an infusion therapy that uses electrical pulses to open up cell membranes, thus optimizing the delivery of DNA vaccines and chemotherapies. The company is developing its MedPulser DNA Electroporation system (which consists of a generator and an applicator inserted into targeted tissue) to deliver chemotherapies directly into tumors. The firm is also exploring the use of the electroporation system for gene therapies and DNA vaccines, which contain large molecules that need assistance getting through cellular walls. In 2008 it agreed to merge with VGX Pharmaceuticals, a developer of DNA vaccines.
View the Comprehensive Company Description for Inovio Biomedical
The Company Description provides a historical perspective of Inovio Biomedical's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Inovio Biomedical's evolution in the marketplace.
